Imugene (ASX:IMU) is planning a phase III blood cancer trial, after the US Food and Drug Administration (FDA) delivered positive feedback on the company’s lead asset, Azer-cel. In effect, the agency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback